Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib maintenance after bevacizumab maintenance in first-line ovarian cancer
2019-000399-41Phase 3Terminated
- Sponsor
- North Eastern German Society of Gynecological Oncology
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Rucaparib maintenance with Placebo (2 arms). Primary endpoint: Progression-free survival in BRCA-negative patients. Started Jun 2019; status: terminated.
02
Drugs
rucaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2019-000399-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000399-41.